Theriva Biologics Advances VCN-01 Dosing Trial for Pancreatic Cancer — Theriva Biologics, Inc.

Event summary

First patients dosed in VIRAGE2 Phase 2a trial for metastatic pancreatic cancer, evaluating more frequent dosing of VCN-01.
Cash runway extends into Q1 2027 with $11.3 million in cash and equivalents as of June 30, 2026.
Phase 1 clinical results for HNSCC published in Clinical Cancer Research, showing prolonged overall survival with VCN-01.
General and administrative expenses decreased by 82% YoY to $2.0 million, while R&D expenses fell by 35% to $1.3 million.

The big picture

Theriva Biologics is advancing its VCN-01 program with a focus on refining dosing regimens for metastatic pancreatic cancer, leveraging feedback from both the EMA and FDA. The company's strategic shift towards more frequent dosing aims to improve treatment outcomes and potentially expand the therapeutic applications of VCN-01 in combination with other cancer interventions. With a cash runway extending into early 2027, Theriva Biologics is positioning itself for critical clinical milestones that could shape its future in the competitive oncology space.

What we're watching

Clinical Progress: Whether the VIRAGE2 trial will successfully demonstrate the safety and feasibility of more frequent VCN-01 dosing, potentially derisking future Phase 3 trials.
Regulatory Dynamics: The outcome of discussions with the FDA in Q3 2026 regarding the proposed Phase 2/3 trial for retinoblastoma, which could impact future development timelines.
Financial Sustainability: How Theriva Biologics will manage its cash runway and secure additional funding to support ongoing clinical trials and operational expenses.